fashion -WSS

fashion

author：focus 2025-08-12 11:28:30 - browse：5355

Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals. -- biotech coverage from STAT — Scientists Christina Frey and Paul Negulescu work in a lab at Vertex Pharmaceuticals in San Diego. Sandy Huffaker for STAT

A pain relief drug developed by Vertex Pharmaceuticals succeeded in late-stage clinical trials, the company announced Tuesday, bringing the biopharma giant a step closer to launching what observers believe could be a potential blockbuster and upending decades of pharma failure in a complicated field.

In a pair of randomized, placebo-controlled Phase 3 trials for patients with pain after a tummy tuck or bunion surgery, the drug showed statistically significant pain reduction compared to placebo, meeting the primary endpoints for these studies and the expectations of market analysts. But the experimental therapy didn’t relieve pain better than a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint observers had been waiting on. And in the bunionectomy trial, the opioid comparator outperformed VX-548 at soothing pain.

The drug, a small molecule known as VX-548, blocks pain-sensing neurons from signaling the pain without the addictive potential of opioids. It was generally safe, with fewer patients on VX-548 reporting adverse events than those taking the placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： STAT series 'Denied by AI' wins major journalism prizes

WSS

Why CTE doesn’t keep Americans from enjoying the Super Bowl

What a koala virus tells us about the human genome

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Unique patient identifier: Experts argue the benefits, pitfalls

Cano Health’s bankruptcy is a warning for Medicare Advantage

Fertility clinic egg and embryo storage is a disaster

focus

fashion

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

What a koala virus tells us about the human genome

Duchenne breakthrough therapy leaves behind pioneering families

Medicare Advantage plans can’t deny care with AI, CMS warns

Medicare details structure of new drug price negotiation program

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Cancer drug shortages should be causing more outrage

The CDC's new social media misinformation war

Continuity nursing helped my family in our darkest PICU moments

Boston hospital trains restaurant workers on naloxone for overdoses

focus

Fertility clinic egg and embryo storage is a disaster

What’s missing from the debate over nursing home staff minimums

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

knowledge

focus

leisure time

explore